Voya Investment Management LLC reduced its position in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) by 6.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,053,616 shares of the company’s stock after selling 431,140 shares during the quarter. Merck & Co., Inc. accounts for approximately 0.8% of Voya Investment Management LLC’s investment portfolio, making the stock its 21st biggest holding. Voya Investment Management LLC owned approximately 0.25% of Merck & Co., Inc. worth $879,651,000 at the end of the most recent reporting period.
A number of other large investors have also recently added to or reduced their stakes in MRK. Curry Webb Wealth Management LLC bought a new stake in shares of Merck & Co., Inc. in the 3rd quarter valued at about $29,000. Horizons Wealth Management acquired a new stake in Merck & Co., Inc. in the 3rd quarter valued at about $30,000. Bullseye Investment Management LLC acquired a new stake in Merck & Co., Inc. in the 2nd quarter valued at about $27,000. Graney & King LLC lifted its stake in Merck & Co., Inc. by 400.0% in the 2nd quarter. Graney & King LLC now owns 250 shares of the company’s stock valued at $32,000 after purchasing an additional 200 shares during the last quarter. Finally, Foresight Capital Management Advisors Inc. bought a new position in Merck & Co., Inc. during the third quarter worth about $43,000. Institutional investors and hedge funds own 76.07% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of brokerages have weighed in on MRK. Berenberg Bank boosted their price target on Merck & Co., Inc. from $127.00 to $137.00 and gave the stock a “hold” rating in a research report on Friday, September 11th. Freedom Broker upped their price objective on Merck & Co., Inc. from $125.00 to $140.00 and gave the company a “hold” rating in a research note on Monday, November 2nd. BMO Capital Markets raised their price objective on Merck & Co., Inc. from $142.00 to $170.00 and gave the company an “outperform” rating in a research report on Thursday, August 20th. UBS Group lifted their target price on Merck & Co., Inc. from $145.00 to $175.00 and gave the stock a “buy” rating in a research note on Thursday, August 20th. Finally, TD Cowen lifted their target price on Merck & Co., Inc. from $137.00 to $155.00 and gave the stock a “hold” rating in a research note on Wednesday, September 23rd. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $155.74.
Check Out Our Latest Analysis on MRK
Merck & Co., Inc. Price Performance
Shares of MRK opened at $143.01 on Wednesday. The firm has a market capitalization of $352.56 billion, a PE ratio of 147.43, a PEG ratio of 6.62 and a beta of 0.13. The company’s 50-day moving average is $145.93 and its 200-day moving average is $128.97. Merck & Co., Inc. has a fifty-two week low of $92.11 and a fifty-two week high of $156.92. The company has a debt-to-equity ratio of 1.11, a current ratio of 1.35 and a quick ratio of 1.14.
Merck & Co., Inc. (NYSE:MRK – Get Free Report) last posted its earnings results on Thursday, October 29th. The company reported $2.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.09 by $0.40. The company had revenue of $18.09 billion during the quarter, compared to analysts’ expectations of $17.33 billion. Merck & Co., Inc. had a net margin of 3.64% and a return on equity of 16.73%. Merck & Co., Inc.’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same quarter last year, the company posted $2.58 EPS. Equities analysts forecast that Merck & Co., Inc. will post 2.82 EPS for the current year.
Merck & Co., Inc. Increases Dividend
The business also recently declared a quarterly dividend, which will be paid on Friday, January 8th. Shareholders of record on Tuesday, December 15th will be issued a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, December 15th. This represents a $3.52 annualized dividend and a yield of 2.5%. This is an increase from Merck & Co., Inc.’s previous quarterly dividend of $0.85. Merck & Co., Inc.’s payout ratio is currently 350.52%.
Insiders Place Their Bets
In other Merck & Co., Inc. news, EVP Richard Deluca sold 58,185 shares of the firm’s stock in a transaction that occurred on Thursday, November 12th. The shares were sold at an average price of $148.01, for a total transaction of $8,611,961.85. Following the completion of the sale, the executive vice president directly owned 112,955 shares in the company, valued at $16,718,469.55. This trade represents a 34.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.17% of the stock is currently owned by corporate insiders.
Latest Merck & Co., Inc. News
Here’s some of the latest news about MRK:
- Positive Sentiment: Merck has reported recent pipeline progress, including positive European committee opinions on expanded indications for ENFLONSIA and WELIREG, as well as Phase 2b results for liver-disease candidate efinopegdutide. These developments support its effort to broaden growth beyond KEYTRUDA. Read More.
- Negative Sentiment: An executive vice president sold 58,185 shares, reducing his holdings by 34%. Insider sales can weigh on sentiment, though a single transaction does not necessarily indicate a change in the company’s outlook. Read More.
- Negative Sentiment: KEYTRUDA patent expirations remain a longer-term concern for revenue, despite recent strength from a newer formulation. Read More.
Merck & Co., Inc. Profile
Merck & Co., Inc. is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company’s research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine. Founded in the United States in 1891, Merck & Co. became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.
Recommended Stories
- Five stocks we like better than Merck & Co., Inc.
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
